<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38961007</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2649</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</Title><ISOAbbreviation>Qual Life Res</ISOAbbreviation></Journal><ArticleTitle>Long-term effects of the COVID-19 pandemic for patients with cancer.</ArticleTitle><Pagination><StartPage>2845</StartPage><EndPage>2853</EndPage><MedlinePgn>2845-2853</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11136-024-03726-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Long COVID is defined as the continuation of symptoms, unexplainable by alternative diagnosis, longer than four weeks after SARS-CoV-2 infection. These symptoms might hinder daily activities and overall well-being, ultimately impacting quality of life (QoL). Several studies have reported fatigue as the most common symptom, followed by dyspnoea, headache and myalgia. Although it is assumed that long COVID affects 10-20% of SARS-CoV-2 infected individuals, recently numbers up to 60% were described for patients with cancer. This study uncovers the impact of the COVID-19 pandemic on QoL of patients with cancer and how long COVID manifests in this cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A group of 96 patients with cancer was followed from March 2022 till March 2023. Online questionnaires assessing symptoms associated with long COVID, anxiety and depression (HADS), quality of life (EORTC-QLQ-C30) and cognitive functioning (CFQ) were sent every three months during this period. Furthermore, a semi-structured focus group was organised for qualitative data collection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, these patients reported a negative impact of the enforced COVID-19 restrictions on the emotional and psychological wellbeing. Forty nine patients with cancer (51.0%) were infected with SARS-CoV-2 over the course of the study, of which 39 (79.6%) reported long COVID symptoms. The most commonly reported symptoms were myalgia (46.2%), fatigue (38.5%) and disturbed sleep (35.9%) and it was observed that male sex is associated with poor long COVID outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While patients with cancer experience similar long COVID symptoms as healthy controls, the prevalence is remarkably higher possibly due to their compromised immune system and weakened physiological reserve.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Debie</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palte</LastName><ForeName>Ziyad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salman</LastName><ForeName>Haya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbruggen</LastName><ForeName>Lise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanhoutte</LastName><ForeName>Greetje</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhajlani</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raats</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roelant</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Trial Center (CTC), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandamme</LastName><ForeName>Timon</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dam</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-9184-7703</Identifier><AffiliationInfo><Affiliation>Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium. Peter.vandam@uza.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium. Peter.vandam@uza.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Qual Life Res</MedlineTA><NlmUniqueID>9210257</NlmUniqueID><ISSNLinking>0962-9343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Since the outbreak in Wuhan (China) at the end of 2019, the Coronavirus Disease 2019 (COVID-19) pandemic has caused instability at various levels of society. While most patients completely recover from their SARS-CoV-2 infection, 10&#x2013;20% of infected persons and up to 60% of infected patients with cancer develop long COVID. Long COVID is defined as the continuation of symptoms, which cannot be explained by alternative causes, that last longer than four weeks after initial infection. Even though it is generally accepted that patients with cancer are at increased risk of developing severe COVID-19, it is still unclear how long COVID manifests and whether long COVID impacts quality of life in this cohort. Hence, this study observed that patients with cancer reported a negative impact of the enforced COVID-19 restrictions on the emotional and psychological wellbeing. While patients with cancer experience similar long COVID symptoms as healthy controls, the prevalence is remarkably higher possibly due to their compromised immune system and weakened physiological reserve.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>18</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>4</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38961007</ArticleId><ArticleId IdType="pmc">PMC11452417</ArticleId><ArticleId IdType="doi">10.1007/s11136-024-03726-9</ArticleId><ArticleId IdType="pii">10.1007/s11136-024-03726-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu, F., et al. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseinzadeh, P. (2022). Social consequences of the COVID-19 pandemic. A systematic review. Invest Educ Enferm, 40(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9052715</ArticleId><ArticleId IdType="pubmed">35485623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz, C. (2023). Long-term effects of COVID-19: A review of current perspectives and mechanistic insights. Critical Reviews in Microbiology, : p. 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">37074754</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam, P., et al. (2021). Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. European Journal of Cancer, 148, 328&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7914028</ArticleId><ArticleId IdType="pubmed">33773276</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeters, M., et al. (2021). Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open, 6(5), 100274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423808</ArticleId><ArticleId IdType="pubmed">34597941</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey, S., et al. (2020). Psychosocial impact of COVID-19. Diabetes Metab Syndr, 14(5), 779&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255207</ArticleId><ArticleId IdType="pubmed">32526627</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma, R., Kilgour, H. M., &amp; Haase, K. R. (2022). The Psychosocial Impact of COVID-19 on older adults with Cancer: A Rapid Review. Current Oncology (Toronto, Ont.), 29(2), 589&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8870801</ArticleId><ArticleId IdType="pubmed">35200553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrosa, A. L., et al. (2020). Emotional, behavioral, and psychological impact of the COVID-19 pandemic. Frontiers in Psychology, 11, 566212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561666</ArticleId><ArticleId IdType="pubmed">33117234</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel, A. N., et al. (2021). Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS One, 16(10), e0259164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553121</ArticleId><ArticleId IdType="pubmed">34710173</ArticleId></ArticleIdList></Reference><Reference><Citation>Said, C. M., Batchelor, F., &amp; Duque, G. (2022). The impact of the COVID-19 pandemic on physical activity, function, and Quality of Life. Clinics in Geriatric Medicine, 38(3), 519&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023337</ArticleId><ArticleId IdType="pubmed">35868670</ArticleId></ArticleIdList></Reference><Reference><Citation>Baffert, K. A., et al. (2021). Quality of life of patients with Cancer during the COVID-19 pandemic. Vivo, 35(1), 663&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880728</ArticleId><ArticleId IdType="pubmed">33402524</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., et al. (2020). Anxiety and depression among tibetan inpatients with cancer: A multicenter investigation. Ann Palliat Med, 9(6), 3776&#x2013;3784.</Citation><ArticleIdList><ArticleId IdType="pubmed">33222453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher, H. (2023). Long COVID in cancer patients: Preponderance of symptoms in majority of patients over long time period. Elife, 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9977271</ArticleId><ArticleId IdType="pubmed">36748905</ArticleId></ArticleIdList></Reference><Reference><Citation>Fankuchen, O., et al. (2023). Long COVID in Cancer: A matched cohort study of 1-year Mortality and Long COVID Prevalence among patients with Cancer who survived an initial severe SARS-CoV-2 infection. American Journal of Clinical Oncology, 46(7), 300&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10280943</ArticleId><ArticleId IdType="pubmed">37072891</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy-Iglesias, M. J., et al. (2022). Long-term effects of COVID-19 on cancer patients: The experience from Guy&#x2019;s Cancer Centre. Future Oncology, 18(32), 3585&#x2013;3594.</Citation><ArticleIdList><ArticleId IdType="pubmed">36172860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal, M., et al. (2021). Assessment and characterisation of post-COVID-19 manifestations. International Journal of Clinical Practice, 75(3), e13746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie, C. E., et al. (2023). True prevalence of long-COVID in a nationwide, population cohort study. Nature Communications, 14(1), 7892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10689486</ArticleId><ArticleId IdType="pubmed">38036541</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini, G., &amp; Aneja, R. (2021). Cancer as a prospective sequela of long COVID-19. Bioessays, 43(6), e2000331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai, C. C., et al. (2023). Long COVID: An inevitable sequela of SARS-CoV-2 infection. Journal of Microbiology, Immunology, and Infection, 56(1), 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="pubmed">36283919</ArticleId></ArticleIdList></Reference><Reference><Citation>Healey, Q., et al. (2022). Symptoms and signs of long COVID: A rapid review and meta-analysis. J Glob Health, 12, 05014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9125197</ArticleId><ArticleId IdType="pubmed">35596571</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., et al. (2023). Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall, M. (2020). The lasting misery of coronavirus long-haulers. Nature, 585(7825), 339&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 38, 101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Debie, Y., et al. (2023). Humoral and Cellular Immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with Cancer. Clinical Cancer Research, 29(3), 635&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">36341493</ArticleId></ArticleIdList></Reference><Reference><Citation>Debie, Y., et al. (2023). Boosting capacity of a fourth dose BNT162b2 in cancer patients. European Journal of Cancer, 179, 121&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9686056</ArticleId><ArticleId IdType="pubmed">36521333</ArticleId></ArticleIdList></Reference><Reference><Citation>Debie, Y. (2021). Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in Cancer patients. European Journal of Cancer.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8714294</ArticleId><ArticleId IdType="pubmed">35077960</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam, P. A. (2022). Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients. ESMO Open, : p. 100414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8818384</ArticleId><ArticleId IdType="pubmed">35305399</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayers, P., et al. (2002). Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. European Journal of Cancer, 38(Suppl 4), S125&#x2013;S133.</Citation><ArticleIdList><ArticleId IdType="pubmed">11858978</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent, D. E., et al. (1982). The cognitive failures questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology, 21(1), 1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7126941</ArticleId></ArticleIdList></Reference><Reference><Citation>Caunt, J. Derbyshire Post Covid Syndrome Questionnaire. Derbyshire Post Covid Syndrome Questionnaire 2020 [cited 2023 24 April].</Citation></Reference><Reference><Citation>Burns, G. Newcastle post-COVID syndrome Follow Up Screening Questionnaire. Newcastle post-COVID syndrome Follow Up Screening Questionnaire 2020 [cited 2023 24 April].</Citation></Reference><Reference><Citation>Turunen, H., Per&#xe4;l&#xe4;, M. L., &amp; Meril&#xe4;inen, P. (1994). [Modification of Colaizzi&#x2019;s phenomenological method; a study concerning quality care]. Hoitotiede, 6(1), 8&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054217</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato, D. J., et al. (2021). Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: Evidence from the OnCovid retrospective, multicentre registry study. The Lancet Oncology, 22(12), 1669&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565932</ArticleId><ArticleId IdType="pubmed">34741822</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue, J. K., et al. (2021). Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open, 4(2), e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, A., et al. (2022). Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Medicine, 28(8), 1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C., et al. (2023). 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet, 401(10393), e21&#x2013;e33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10258565</ArticleId><ArticleId IdType="pubmed">37321233</ArticleId></ArticleIdList></Reference><Reference><Citation>Magasi, S. (2022). Cancer Survivors&#x2019; Disability Experiences and Identities: A Qualitative Exploration to Advance Cancer Equity. International Journal of Environmental Research and Public Health, 19(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8910238</ArticleId><ArticleId IdType="pubmed">35270802</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook, H., et al. (2021). Long covid-mechanisms, risk factors, and management. Bmj, 374, n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tze, H., et al. (2020). Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Supportive Care in Cancer, 28(1), 211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">31001695</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden, W., et al. (2012). Anxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age. Journal of Affective Disorders, 141(2&#x2013;3), 343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">22727334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ci&#x105;&#x17c;y&#x144;ska, M., et al. (2020). Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic. Psychooncology, 29(9), 1377&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323427</ArticleId><ArticleId IdType="pubmed">32779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeppesen, S. S., et al. (2021). Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS). Acta Oncologica, 60(1), 4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">33031010</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper, F. P., et al. (2023). Alpha to Omicron: Disease Severity and Clinical outcomes of Major SARS-CoV-2 variants. Journal of Infectious Diseases, 227(3), 344&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619650</ArticleId><ArticleId IdType="pubmed">36214810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Aceituno, A., Garcia-Hernandez, A., &amp; Larumbe-Zabala, E. (2023). COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Infect Dis Now, 53(5), 104688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="pubmed">36858287</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld, M. S., et al. (2023). Factors Associated with Long COVID symptoms in an online cohort study. Open Forum Infect Dis, 10(2), ofad047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945931</ArticleId><ArticleId IdType="pubmed">36846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini, A., et al. (2023). SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: Results from the OnCovid registry. The Lancet Oncology, 24(4), 335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9991062</ArticleId><ArticleId IdType="pubmed">36898391</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren, O., et al. (2023). Effect of covid-19 vaccination on long covid: Systematic review. BMJ Med, 2(1), e000385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte, K. I., et al. (2022). Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine, 53, 101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>